Tarsus Pharmaceuticals, Inc.
TARS
Updated: 23/09/2026, 20:37:07
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
No summaries found.
- Share price
- $75.07
- Market cap
- $3.24B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Bobak R. Azamian
- Employees
- 370
- IPO date
- 16/10/2020
- Beta
- 0.541
- Last dividend
- $0.00
- Day range
- $74.46 – $77.26
- 52-week range
- $53.89 – $91.53
- 1-day performance
- -2.61%
- 1-year performance
- 39.30%
- Current drawdown (1Y)
- -17.98%
- CIK
- 0001819790
- CUSIP
- 87650L103
- ISIN
- US87650L1035
- Created
- 07/12/2025, 14:29:48
- Last update
- 23/09/2026, 20:37:07
Track Tarsus Pharmaceuticals, Inc. with an AI analyst
See which prediction-market events move TARS, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Tarsus to Participate in Upcoming Investor Conferences
GlobeNewsWire • STOCK • 28/05/2026, 18:30:00
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 12/05/2026, 23:20:44
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2026 Earnings Call Transcript
Seeking Alpha • STOCK • 06/05/2026, 23:41:16
Tarsus Pharmaceuticals: Marketing Spend Bears Fruit, Pipeline Progresses
Seeking Alpha • STOCK • 14/04/2026, 03:44:02
Tarsus Pharmaceuticals, Inc. (TARS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Seeking Alpha • STOCK • 11/03/2026, 15:42:22
Tarsus to Participate in Upcoming Investor Conferences
GlobeNewsWire • STOCK • 26/02/2026, 17:30:00
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q4 Loss, Beats Revenue Estimates
Zacks Investment Research • STOCK • 23/02/2026, 21:26:10
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors
GlobeNewsWire • STOCK • 18/02/2026, 09:30:00